These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25867020)

  • 1. Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors.
    Wu W; Dong Y; Gao J; Gong M; Zhang X; Kong W; Li Y; Zeng Y; Si D; Wei Z; Ci X; Jiang L; Li W; Li Q; Yi X; Liu C
    Cancer Sci; 2015 Jun; 106(6):747-756. PubMed ID: 25867020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance.
    Liu Y; Zhou Z; Lin X; Xiong X; Zhou R; Zhou M; Huang Y
    Biomacromolecules; 2019 Oct; 20(10):3755-3766. PubMed ID: 31465208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.
    Kobayashi E; Iyer AK; Hornicek FJ; Amiji MM; Duan Z
    Clin Orthop Relat Res; 2013 Mar; 471(3):915-25. PubMed ID: 23011844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of saikosaponin D on doxorubicin pharmacokinetics and its MDR reversal in MCF-7/adr cell xenografts.
    Li C; Xue HG; Feng LJ; Wang ML; Wang P; Gai XD
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4437-4445. PubMed ID: 29077148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
    Wang C; Wei X; Shao G
    Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells.
    Ai S; Jia T; Ai W; Duan J; Liu Y; Chen J; Liu X; Yang F; Tian Y; Huang Z
    Br J Pharmacol; 2013 Apr; 168(7):1719-35. PubMed ID: 23146125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
    Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
    Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
    Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
    Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition.
    Rouibah H; Kebsa W; Lahouel M; Zihlif M; Ahram M; Aburmeleih B; Mustafa E; Al-Ameer HJ
    Anticancer Agents Med Chem; 2018; 18(3):375-387. PubMed ID: 29318976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R; Mayer LD
    Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in P-glycoprotein expression in mouse tissues by doxorubicin: implications for pharmacokinetics in multiple dosing regimens.
    Gustafson DL; Long ME
    Chem Biol Interact; 2001 Oct; 138(1):43-57. PubMed ID: 11640914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia.
    Sadzuka Y; Sugiyama T; Sawanishi H; Miyamoto K
    Cancer Lett; 1999 Apr; 138(1-2):5-11. PubMed ID: 10378767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein.
    Zhang FY; Du GJ; Zhang L; Zhang CL; Lu WL; Liang W
    Pharm Res; 2009 Apr; 26(4):914-25. PubMed ID: 19067124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE; Mayer LD
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
    Toffoli G; Corona G; Gigante M; Boiocchi M
    Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
    Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
    Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
    Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
    Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide releasing d-α-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin.
    Song Q; Tan S; Zhuang X; Guo Y; Zhao Y; Wu T; Ye Q; Si L; Zhang Z
    Mol Pharm; 2014 Nov; 11(11):4118-29. PubMed ID: 25222114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.